What's in Seref istek's pipeline?

Seref istek has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Seref istek's portfolio?

Top competitors by shared drug class: Arbor Pharmaceuticals, Inc., Innogene Kalbiotech Pte. Ltd, Medical University of Silesia, The Hospital for Sick Children, Université de Sherbrooke.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/seref-istek.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Seref istek — Portfolio Competitive Intelligence Brief

Seref istek pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
*AS 50% eye drops 81**	AS 50% eye drops 8*1	marketed	Osmotic agent		Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Arbor Pharmaceuticals, Inc. · 1 shared drug class
Innogene Kalbiotech Pte. Ltd · 1 shared drug class
Medical University of Silesia · 1 shared drug class
The Hospital for Sick Children · 1 shared drug class
Université de Sherbrooke · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seref istek:

Cite this brief

Drug Landscape (2026). Seref istek — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seref-istek. Accessed 2026-05-15.